Key takeaways
- Levothyroxine remains first-line treatment for primary hypothyroidism in NICE guidance. Liothyronine is not routinely recommended alone or in combination. NICE thyroid guideline.
- T4 provides hormone that the body can convert to T3; adding T3 changes the pattern of hormone exposure, not simply the “strength” of treatment. American Thyroid Association explanation.
- Persistent symptoms deserve review even when TSH is in range. NICE advises considering FT4 testing as well in people still symptomatic on treatment. NICE monitoring recommendations.
- Research has not established consistent superiority of combined T4/T3 treatment, although carefully selected, supervised trials remain a clinical discussion. ATA summary of the joint consensus.
- Too much thyroid hormone can cause heart-rhythm problems and bone loss. Feeling more stimulated is not proof of better replacement. ATA treatment information.
Being told your thyroid result is normal while you still feel exhausted can leave you wondering what the test has missed. It is a reasonable question. The answer should be a review of treatment and symptoms, not an automatic dismissal or an automatic T3 prescription.
Eltroxin and Synthroid are levothyroxine brands, containing T4. Cytomel contains liothyronine, or T3. The difference is about how thyroid hormone is supplied and handled by the body, rather than an older medicine versus an inherently better one. South African Eltroxin leaflet, ATA explanation.
How do T4 and T3 differ?
T4 provides a relatively steady supply that the body can convert to T3; liothyronine produces a shorter-acting pattern.
The thyroid makes mainly T4 and a smaller amount of T3. Other tissues convert T4 to T3, and this conversion continues even when the thyroid is diseased or has been removed. The ATA describes a rapid rise in blood T3 after a Cytomel tablet followed by a rapid fall. Levothyroxine remains in the body longer, providing a steadier supply. High T3 peaks can cause a racing heart, insomnia and anxiety. ATA explanation.
| Feature | Levothyroxine: T4 | Liothyronine: T3 |
|---|---|---|
| Examples of brand names | Eltroxin, Synthroid | Cytomel |
| Hormone supply | Converted to T3 as part of normal physiology | Supplies T3 directly |
| Usual role in primary hypothyroidism | Standard first-line replacement | Not routinely used; selected specialist discussions |
| Main comparison question | Is replacement consistent and adequate? | Is there a justified reason to change the exposure pattern? |
What can affect treatment or thyroid test results?
Biotin can distort blood-test results, while food and some medicines interfere with levothyroxine absorption.
In NICE’s guidance, a very high TSH before treatment or a long period of untreated hypothyroidism can require up to 6 months for TSH to return to range. That delay needs to be considered during adjustment. Treatment should address symptoms while keeping TSH in range, without suppressing it or causing thyroid-hormone excess. NICE recommendations.
For an adult still symptomatic on levothyroxine, NICE advises considering an FT4 test alongside TSH. Tell the clinician about biotin supplements before testing. High biotin intake can produce either falsely high or falsely low thyroid results.
The local Eltroxin leaflet says to take it on an empty stomach, preferably at least half an hour before breakfast. Food, iron, calcium, soya and some antacids can reduce absorption. Ask the pharmacist about timing for the products you use. Eltroxin instructions.
Amiodarone, lithium, phenytoin and carbamazepine are among the medicines the ATA lists as potentially changing thyroid replacement requirements. Report a brand or manufacturer change too, so the clinician can consider rechecking levels. Follow the clinician’s or laboratory’s blood-test instructions; do not assume every thyroid test requires fasting. ATA practical guidance.
The diagnosis, treatment routine and other possible causes of symptoms need review before adding T3. Symptoms should not be reduced to a laboratory number, but a normal result is not proof of a hidden conversion defect either. Our depression and cognitive symptoms article explores another clinical setting in which fatigue or concentration difficulties may need attention.
Is a supervised T4/T3 trial ever reasonable?
It can be discussed for selected patients, but it is not an established upgrade for everyone who remains tired.
The American, British and European thyroid associations convened 12 experts to assess combination treatment. Their review found no consistent benefit in the available trials, but limitations prevented a definite conclusion. They proposed future trials lasting at least a year, with standard measures of thyroid-related quality of life. They also called for research on genetic changes in type 2 deiodinase, an enzyme involved in T4-to-T3 conversion. Those changes have an uncertain clinical impact; persistent fatigue does not establish that an individual has one. ATA consensus summary.
The ATA patient page suggests that a 3 to 6 month trial may be reasonable for some people who remain unwell on T4 alone. NICE advises against routine liothyronine, alone or combined, because superiority is unproven and long-term adverse effects remain uncertain. These positions allow discussion of a selected patient’s supervised trial without promising benefit to everyone. ATA treatment information, NICE guideline.
Agree what improvement would justify continuing, when thyroid levels will be checked and when an unsuccessful trial will end. The consensus proposes thyroid-specific questionnaires for future research and patient preference as a secondary outcome. A brief burst of energy is insufficient evidence of sustained benefit. Consensus assessment proposals.
When should symptoms prompt a quicker review?
Palpitations, tremor or new sleep disturbance may indicate excessive hormone exposure and should be discussed promptly. Eltroxin patient leaflet.
Chest pain or a significant new heart-rhythm problem needs urgent assessment. Eltroxin’s warnings also address bone loss with a low TSH despite normal T3 and T4, and the risk during long-term treatment after menopause. Discuss those risks with the prescriber. Eltroxin is not indicated for obesity or weight loss; do not increase thyroid hormone for weight loss or extra energy. Local warnings. Our prolactin guide covers investigation of a different abnormal hormone result. An abnormal result needs its cause identified before treatment is added.
Do and don’t
Do:
- Bring symptoms, test results, supplements and your actual medicine pack to the review.
Don’t:
- Substitute T3 for T4 yourself or chase a suppressed TSH.
- Assume persistent fatigue proves poor T4-to-T3 conversion.
